| Literature DB >> 29032324 |
Britney Keech1, Simon Crowe2, Darren R Hocking3.
Abstract
Deficits in social cognition are pervasive and characteristic of neurodevelopmental disorders (NDDs). Clinical trials of intranasal oxytocin (IN-OT) to improve social cognition have yielded inconclusive results. The current study is a meta-analysis of randomized controlled trials (RCTs) considering the effect of IN-OT on social cognitive domains across a range of NDDs. Medline, PsychINFO and Scopus were searched for RCTs published through to July 25, 2017. Seventeen studies met inclusion criteria, comprising 466 participants with a NDD. Meta-analysis using a random-effects model, revealed that IN-OT had no significant effect on emotion recognition (Hedges' g=0.08), a moderate but non-significant effect on empathy (Hedges' g=0.49), and a small, significant effect on theory of mind (ToM) (Hedges' g=0.21). Meta-regression indicated that the effect of IN-OT on social cognition was not moderated by the diagnosis or age of participants, or the dose or frequency of IN-OT administration. The results highlight a need for more well-designed RCTs, as it remains difficult to draw conclusions about the potential for IN-OT to improve social cognition in NDDs. The promise of IN-OT should be considered tentative.Entities:
Keywords: Autism; Intranasal; Neurodevelopmental disorder; Oxytocin; Schizophrenia; Social cognition
Mesh:
Substances:
Year: 2017 PMID: 29032324 DOI: 10.1016/j.psyneuen.2017.09.022
Source DB: PubMed Journal: Psychoneuroendocrinology ISSN: 0306-4530 Impact factor: 4.905